185 related articles for article (PubMed ID: 37005303)
21. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
[TBL] [Abstract][Full Text] [Related]
22. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.
Zhuo M; Li J; Buckley LF; Tummalapalli SL; Mount DB; Steele DJR; Lucier DJ; Mendu ML
Kidney360; 2022 Mar; 3(3):455-464. PubMed ID: 35582176
[TBL] [Abstract][Full Text] [Related]
23. The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study.
Ziser KED; Wood S; Tan GSQ; Morton JI; Shaw JE; Bell JS; Ilomaki J
J Diabetes; 2024 Apr; 16(4):e13507. PubMed ID: 38599885
[TBL] [Abstract][Full Text] [Related]
24. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus.
Lee SE; Nam H; Choi HS; Kim H; Kyoung DS; Kim KA
Diabetes Metab J; 2022 Jul; 46(4):567-577. PubMed ID: 35130688
[TBL] [Abstract][Full Text] [Related]
25. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
Sung HL; Hung CY; Tung YC; Lin CC; Tsai TH; Huang KH
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3784. PubMed ID: 38402457
[TBL] [Abstract][Full Text] [Related]
26. Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan.
Tsai HR; Lin YJ; Yeh JI; Lin SM; Liu PP; Chang YC; Lee YC; Loh CH; Huang HK
Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):19. PubMed ID: 38864813
[TBL] [Abstract][Full Text] [Related]
27. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study.
Chen J; Chang J; Shi Q; Li X; Wang L; Zhao H
BMC Cardiovasc Disord; 2023 Oct; 23(1):495. PubMed ID: 37805494
[TBL] [Abstract][Full Text] [Related]
29. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.
Permana H; Audi Yanto T; Ivan Hariyanto T
Diabetes Res Clin Pract; 2023 Jan; 195():110205. PubMed ID: 36502891
[TBL] [Abstract][Full Text] [Related]
30. Should Baseline Hemoglobin A
Uhrig JL; Page SO; Mishriky BM; Patil SP; Powell JR; Sewell K; Mian MR; Cummings DM
J Clin Pharmacol; 2020 Aug; 60(8):980-991. PubMed ID: 32396236
[TBL] [Abstract][Full Text] [Related]
31. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
[TBL] [Abstract][Full Text] [Related]
32. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018.
Engler C; Leo M; Pfeifer B; Juchum M; Chen-Koenig D; Poelzl K; Schoenherr H; Vill D; Oberdanner J; Eisendle E; Middeldorf K; Heindl B; Gaenzer H; Bode G; Kirchmeyr K; Ladner G; Rieger L; Koellensperger U; Schwaiger A; Stoeckl F; Zangerl G; Lechleitner M; Delmarko I; Oberaigner W; Rissbacher C; Tilg H; Ebenbichler C
BMJ Open Diabetes Res Care; 2020 Sep; 8(1):. PubMed ID: 32873600
[TBL] [Abstract][Full Text] [Related]
33. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
[TBL] [Abstract][Full Text] [Related]
34. The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
Bendotti G; Montefusco L; Pastore I; Lazzaroni E; Lunati ME; Fiorina P
J Endocrinol Invest; 2023 Dec; 46(12):2445-2452. PubMed ID: 37535237
[TBL] [Abstract][Full Text] [Related]
35. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
Singh AK; Singh R
Diabetes Res Clin Pract; 2021 Feb; 172():108536. PubMed ID: 33181201
[TBL] [Abstract][Full Text] [Related]
36. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database.
Tanabe M; Nomiyama T; Motonaga R; Murase K; Yanase T
BMC Endocr Disord; 2015 Sep; 15():49. PubMed ID: 26382923
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
38. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.
Bouchi R; Sugiyama T; Goto A; Imai K; Ihana-Sugiyama N; Ohsugi M; Yamauchi T; Kadowaki T; Ueki K
J Diabetes Investig; 2022 Feb; 13(2):280-291. PubMed ID: 34309213
[TBL] [Abstract][Full Text] [Related]
39. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
Qian D; Zhang T; Tan X; Zheng P; Liang Z; Xie J; Jiang J; Situ B
PLoS One; 2018; 13(8):e0202563. PubMed ID: 30148851
[TBL] [Abstract][Full Text] [Related]
40. Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.
Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Raparelli V; Pilote L
Int J Cardiol; 2020 Jul; 310():147-154. PubMed ID: 32303419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]